These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11092049)

  • 1. Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma.
    Curry BJ; Myers K; Hersey P
    Recent Results Cancer Res; 2001; 158():211-30. PubMed ID: 11092049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma.
    Curry BJ; Myers K; Hersey P
    J Clin Oncol; 1998 May; 16(5):1760-9. PubMed ID: 9586889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases.
    Curry BJ; Myers K; Hersey P
    J Clin Oncol; 1999 Aug; 17(8):2562-71. PubMed ID: 10561323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
    Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
    J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
    Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
    J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
    Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction.
    Goydos JS; Ravikumar TS; Germino FJ; Yudd A; Bancila E
    J Am Coll Surg; 1998 Aug; 187(2):182-8; discussion 188-90. PubMed ID: 9704966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma.
    Brownbridge GG; Gold J; Edward M; MacKie RM
    Br J Dermatol; 2001 Feb; 144(2):279-87. PubMed ID: 11251559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness.
    Blaheta HJ; Paul T; Sotlar K; Maczey E; Schittek B; Paul A; Moehrle M; Breuninger H; Bueltmann B; Rassner G; Garbe C
    Br J Dermatol; 2001 Aug; 145(2):195-202. PubMed ID: 11531779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma.
    Mocellin S; Del Fiore P; Guarnieri L; Scalerta R; Foletto M; Chiarion V; Pilati P; Nitti D; Lise M; Rossi CR
    Int J Cancer; 2004 Sep; 111(5):741-5. PubMed ID: 15252844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression.
    Strohal R; Mosser R; Kittler H; Wolff K; Jansen B; Brna C; Stingl G; Pehamberger H
    Melanoma Res; 2001 Oct; 11(5):543-8. PubMed ID: 11595894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma.
    Blaheta HJ; Ellwanger U; Schittek B; Sotlar K; MacZey E; Breuninger H; Thelen MH; Bueltmann B; Rassner G; Garbe C
    J Invest Dermatol; 2000 Apr; 114(4):637-42. PubMed ID: 10733666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma.
    Schmidt H; Sorensen BS; Sjoegren P; Christensen IJ; Fode K; Larsen J; Nexo E; von der Maase H
    J Invest Dermatol; 2006 Apr; 126(4):849-54. PubMed ID: 16410782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.
    Hasselmann DO; Rappl G; Rössler M; Ugurel S; Tilgen W; Reinhold U
    Oncol Rep; 2001; 8(1):115-8. PubMed ID: 11115581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
    Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
    J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients.
    Schittek B; Blaheta HJ; Ellwanger U; Garbe C
    Recent Results Cancer Res; 2001; 158():93-104. PubMed ID: 11092036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients.
    Osella-Abate S; Savoia P; Quaglino P; Fierro MT; Leporati C; Ortoncelli M; Bernengo MG
    Br J Cancer; 2003 Oct; 89(8):1457-62. PubMed ID: 14562017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.